A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

Samankaltaisia teoksia

• Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis
  Tekijä: van der Heijde, D, et al.
  Julkaistu: (2006)
• Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE
  Tekijä: Papp, K.A., et al.
  Julkaistu: (2015)
• A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis
  Tekijä: Lee, Joo-Heung, et al.
  Julkaistu: (2016)
• Combination of Etanercept and Twice-Weekly Administration of Cyclosporin in Psoriasis Unsatisfactorily Controlled by Etanercept Monotherapy: A Retrospective Analysis
  Tekijä: G.A. Vena, et al.
  Julkaistu: (2012-08-01)
• Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers
  Tekijä: Jackson, Akil, et al.
  Julkaistu: (2010)